Krystal Biotech, Inc. (KRYS)
NASDAQ
Closed
Sep 22, 2026
Day's Range
334.3152 wk Range
158.08Overview - KRYS - Krystal Biotech, Inc.
Key Statistics
Valuation
Enterprise Value
9.76B
P/E (Trailing)
‪44.89‬
P/E (Forward)
‪38.12‬
PEG Ratio
‪1.14‬
Price / Sales (TTM)
‪24.07‬
Price / Book
‪7.80‬
EV / EBITDA
‪49.00‬
Profitability
Gross Margin
‪94.60%‬
Profit Margin
‪54.81%‬
Operating Margin
‪48.99%‬
Return on Assets
‪9.36%‬
Return on Equity
‪20.12%‬
Ownership
Shares Outstanding
29.59M
Float
23.56M
Short % of Shares Outstanding
‪17.72%‬
Held by Insiders
‪10.82%‬
Held by Institutions
‪102.55%‬
Price stats
Beta
‪0.53‬
50-Day Avg
‪349.76‬
200-Day Avg
‪290.32‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
11 analysts
Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - KRYS - Krystal Biotech, Inc.
Peers - KRYS - Krystal Biotech, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- KRYSNASDAQKrystal Biotech, Inc.10.60BMarket Cap+59.60%52-week change44.89P/E (Trailing)‪54.81%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - KRYS - Krystal Biotech, Inc.
About
Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for serious and rare diseases. Its lead product, VYJUVEK, is a redosable gene therapy approved for dystrophic epidermolysis bullosa, a rare inherited skin disorder.…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
